
# Table 1: Definitions of selected terms used in the recommendations and upgraded position statements for GIOP
| **Term**                                                     | **Adults ≥40 years of age**                                         | **Adults <40 years of age**                                             |
|--------------------------------------------------------------|---------------------------------------------------------------------|------------------------------------------------------------------------|
| **Major osteoporotic fracture (MOF)**                        | Non-traumatic or pathological fractures of the spine, hip, wrist, or humerus | Non-traumatic or pathological fractures of the spine, hip, wrist, or humerus |
| **Clinical fracture risk assessment**                        | History of GC use, evaluation for falls, fractures, frailty, secondary causes of OP, FRAX® with GC adjustment, BMD with VFA or spinal x-ray | History of GC use, evaluation for falls, fractures, frailty, secondary causes of OP, BMD with VFA or spinal x-ray (FRAX® not validated at age <40 years) |
| **Follow up risk assessment during GC treatment**            | BMD with VFA or spinal x-ray every 1-2 years during OP therapy | BMD with VFA or spinal x-ray every 1-2 years during OP therapy |
|                                                              | BMD with VFA or spinal x-ray every 1-2 years after OP therapy is discontinued | BMD with VFA or spinal x-ray every 1-2 years after OP therapy is discontinued |
| **FRAX® GC correction**                                      | If GC dose is >7.5 mg/day, multiply the 10-year risk of major osteoporotic fracture by 1.15 and the hip fracture risk by 1.2 | *Not applicable as FRAX® is not validated in this age group* |
| **Very high fracture risk**                                  | Prior OP fracture(s) OR BMD T score ≤ -3.5 OR FRAX® (GC-Adjusted*) 10-year risk of MOF ≥30% or hip ≥4.5% OR High GC ≥30 mg/day for >30 days OR cumulative doses ≥5 g/year | Prior fracture(s) OR GC ≥30mg/day OR cumulative ≥5grams/year |
| **High fracture risk**                                       | BMD T score ≤ -2.5 but > -3.5 OR FRAX® (GC-Adjusted*) 10-year risk of MOF ≥20% but <30% or hip ≥3% but <4.5% | BMD T score ≤ -2.5 but > -3.5 OR FRAX® (GC-Adjusted*) 10-year risk of MOF ≥20% but <30% or hip ≥3% but <4.5% |
| **Moderate fracture risk**                                   | FRAX® (GC-Adjusted) 10-year risk of MOF ≥10 and <20%, hip >1 and <3% OR BMD T score between -1 and -2.4 | Continuing GC treatment ≥7.5mg/day for ≥6 months AND BMD Z score < -3 OR significant BMD loss (> least significant change of DXA) |
| **Low fracture risk**                                        | FRAX® (GC-Adjusted) 10-year risk of MOF <10%, hip <1 %, BMD > -1.0 | None of the above risk factors other than GC treatment |
| **Recommended treatment strategy**                            | Calcium and Vitamin D, Bisphosphonates (oral or IV), PTH/PTHrP Agonists, Denosumab, Raloxifene, Romosozumab | Calcium and Vitamin D, Bisphosphonates (oral or IV), PTH/PTHrP Agonists, Denosumab, Raloxifene, Romosozumab |
| **Calcium and Vitamin D**                                     | Optimized intake of dietary and supplemental calcium and vitamin D based on age-appropriate U.S. Recommended Dietary Allowances. | Optimized intake of dietary and supplemental calcium and vitamin D based on age-appropriate U.S. Recommended Dietary Allowances. |
| **Bisphosphonates (BP)** <br> Alendronate (oral) <br> Risedronate (oral) <br> Ibandronate (oral/ IV) <br> Zoledronic acid (IV) <br> **PTH & PTHrP Agonists** <br> Teriparatide (TER) <br> Abaloparatide (ABL) <br> **Anti-RANKL** <br> Denosumab (DEN) <br> **Selective Estrogen Receptor Modulator** <br> Raloxifene (RAL) <br> **Anti-sclerostin** <br> Romosozumab (ROM) | We strongly recommend OP treatment for those at moderate, high or very high risk of fracture. <br> We strongly recommend oral BP over no treatment in high and very high fracture risk due to fracture reduction in GIOP. <br> We conditionally recommend PTH/PTHrP over anti-resorptives in patients at very high risk of fracture. <br> We conditionally recommend DEN$& or PTH/PTHrP over oral and IV BP in high risk of fracture. <br> We conditionally recommend IV BP, ROM, RAL over no treatment in high and very high risk of fracture. <br> In moderate risk, we conditionally recommend BP, DEN, or PTH/PTHrP in no preferred order among these agents. <br> Except in patients intolerant of other agents, we conditionally recommend against RAL due to harms of VTE and fatal stroke or ROM due to uncertain harms with increased myocardial infarction, stroke and death. | We conditionally recommend treatment for those at moderate or very high risk of fracture with oral or IV BP$, PTH/PTHrP% or DEN%&. <br> We conditionally recommended against RAL due to harms of VTE and fatal stroke or ROM due to uncertain harms including increased myocardial infarction, stroke and death. |

# Table 2. Recommendations for initial treatment for prevention of GIOP in adults beginning long-term GC therapy

|Recommendations for patients taking prednisone ≥2.5mg/day for >3months|Certainty of evidence|PICO evidence report basis|Page no(s). of evidence tables|
|---|---|---|---|
|For adults and children beginning or continuing chronic GC treatment at low, moderate, high, or very high risk of fracture, we conditionally recommend optimizing dietary and supplemental calcium and vitamin D in addition to lifestyle modifications (CAL/VIT D/LM)|Low or Very Low|1.1a,b,c-1.3a,b,c, 2.1-2.3, 7.16-7.26|6-8, 47-48, 63-65, 141-144, 148-151|
|In adults ≥40 years (All additional recommendations are in addition to CAL/VIT D/LM.)| | | |
|For adults ≥40 years with HIGH or VERY HIGH fracture risk, we strongly recommend OP therapy over no treatment. Agents to use include oral BP#, IV BP$, PTH/PTHrP$, DEN$, RAL or ROM.|Low or Very Low|1.4c-1.28c|6-50|
|For adults ≥40 years with VERY HIGH fracture risk, we conditionally recommend PTH/PTHrP over anti-resorptive (DEN, BP) treatment.|Low|1.13c-1.20c|49-50|
|For adults ≥40 years with HIGH fracture risk, we conditionally recommend PTH/PTHrP or DEN over BP treatment.|Low|1.13c-1.20c|49-50|
|For adults ≥40 years with HIGH or VERY HIGH fracture risk, we strongly recommend oral BP over no treatment.|Low|1.4c|8-18|
|For adults ≥40 years with HIGH or VERY HIGH fracture risk, we conditionally recommend using ROM or RAL in patients intolerant of other agents.|Very low|1.16c, 1.21c, 1.28c|50|
|For adults ≥40 years with HIGH or VERY HIGH fracture risk, we conditionally recommend against using two different OP medications.|Very Low|1.29-1.35|53-62|
|For adults ≥40 years with MODERATE fracture risk, we conditionally recommend against ROM except for in patients intolerant of other agents, due to risk of myocardial infarction, stroke or death.|Very Low|1.12b, 1.16b, 1.17b, 1.21b-1.25b, 1.28b|40-41, 44-47|
| For adults ≥40 years with LOW fracture risk, we strongly recommend against OP medications in addition to CAL/VIT D/ LM due to known risk of harms and no evidence of benefit. | Very low | 4.4a-4.13a | 91-101 |
|Adults receiving high-dose GC (initial dose ≥30 mg/day for >30 days or cumulative dose ≥5 gm in 1 year)
| | | |
|We conditionally recommend treating with PTH/PTHrP over anti-resorptives.|Low|6.1b--6.19a|120-141|
|Oral BP are strongly recommended over no treatment.|Low|6.1b -6.19a|120-141|
|IV BP and DEN are conditionally recommended over no treatment.|Low|6.1b -6.19a|120-141|
|RAL and ROM are conditionally recommended in those intolerant of other agents.|Low|6.1b -6.19a|120-141|
|In adults <40 years (All additional recommendations are in addition to CAL/VIT D/LM.)| | | |
| For adults <40 years with MODERATE fracture risk, we conditionally recommended oral or IV BP%, DEN%, or PTH/PTHrP therapy. | Low or Very low | 2.4-2.22, 3.4-3.17 | 65-76, 79-84 |
| For adults <40 years with MODERATE fracture risk, we conditionally recommended against using ROM due to risk of myocardial infarction, stroke or death. | Very Low | 2.9, 3.9 | 70, 87 |
|For adults with solid organ transplants Glomerular filtration rate ≥35 ml/minute, and no evidence of chronic kidney disease-mineral and bone disorder (CKD-MBD) or hyperparathyroidism| | | |
|We conditionally recommend expert evaluation for CKD-MBD in renal transplant recipients.|Low|5.1-5.26|103-118|
|We conditionally recommend treatment with oral or IV BP, DEN, PTH/PTHrP, or RAL based on individual patient factors.|Low|5.1-5.26|103-118|
|We conditionally recommended against using ROM due to risk of myocardial infarction, stroke or death.|Very low|5.9|112|
|Children ages 4-17 years treated with GCs for >3 months (low and moderate risk)| | | |
|We conditionally recommended optimization of dietary and supplementation of CAL and VIT D as recommended by U.S. RDA depending on the age of the child.|Very low|7.1a-7.4a|141-144|
|We conditionally recommended against starting oral or IV BP due to low risk of OP fractures in this age group.|Very Low|7.5a|144|
|Children ages 4-17 years with an osteoporotic fracture Who are continuing treatment with GCs at a dose of ≥0.1 mg/kg/day for >3 months (high risk)| | | |
| We conditionally recommend treating with an oral or IV BP. | Very low | 7.1b-7.2b | 148-153 |


# Sequential Treatments Recommended When Initial OP Therapy and GC are Discontinued and at Low or Moderate Risk

|Initial OP therapy|Subsequent OP therapy options|
|---|---|
|Oral/IV Bisphosphonate|No subsequent OP therapy needed|
|RAL|No subsequent OP therapy needed|
|PTH/PTHrP|Oral or IV Bisphosphonate|
|Denosumab|Oral or IV Bisphosphonate|
|Romosozumab|Oral or IV Bisphosphonate|

# Sequential treatments when a new fracture occurs after ≥12 months of initial OP therapy

|Initial OP therapy|Subsequent OP therapy options|
|---|---|
|Oral/IV Bisphosphonate|DEN, PTH/PTHrP, ROM|
|RAL|Oral or intravenous BP, PTH/PTHrP, DEN, ROM|
|PTH/PTHrP|Oral or intravenous BP, DEN|
|Denosumab|Oral or IV Bisphosphonate, ROM|
|Romosozumab|Oral or IV Bisphosphonate, DEN|
